There are roughly 80,000 newly diagnosed bladder cancer cases each year in China and 70-80% are early-stage cancers, otherwise known as non-muscle invasive bladder cancer (NMIBC). The current standard care for high-risk patients who failed intravesical therapies is surgical removal of the bladder, which drastically lowers the patient’s quality of life.
Now, Shanghai-based Asieris Pharma is developing an old antibiotic – a methionine aminopeptidase II (MetAP2) inhibitor – as a repurposed...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?